172 related articles for article (PubMed ID: 35788128)
1. Targeting the methionine-methionine adenosyl transferase 2A- S -adenosyl methionine axis for cancer therapy.
Guo J; Yang Y; Buettner R; Rosen ST
Curr Opin Oncol; 2022 Sep; 34(5):546-551. PubMed ID: 35788128
[TBL] [Abstract][Full Text] [Related]
2. Overview of Methionine Adenosyltransferase 2A (MAT2A) as an Anticancer Target: Structure, Function, and Inhibitors.
Li C; Gui G; Zhang L; Qin A; Zhou C; Zha X
J Med Chem; 2022 Jul; 65(14):9531-9547. PubMed ID: 35796517
[TBL] [Abstract][Full Text] [Related]
3. Targeting S-adenosylmethionine biosynthesis with a novel allosteric inhibitor of Mat2A.
Quinlan CL; Kaiser SE; Bolaños B; Nowlin D; Grantner R; Karlicek-Bryant S; Feng JL; Jenkinson S; Freeman-Cook K; Dann SG; Wang X; Wells PA; Fantin VR; Stewart AE; Grant SK
Nat Chem Biol; 2017 Jul; 13(7):785-792. PubMed ID: 28553945
[TBL] [Abstract][Full Text] [Related]
4. Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous
Konteatis Z; Travins J; Gross S; Marjon K; Barnett A; Mandley E; Nicolay B; Nagaraja R; Chen Y; Sun Y; Liu Z; Yu J; Ye Z; Jiang F; Wei W; Fang C; Gao Y; Kalev P; Hyer ML; DeLaBarre B; Jin L; Padyana AK; Dang L; Murtie J; Biller SA; Sui Z; Marks KM
J Med Chem; 2021 Apr; 64(8):4430-4449. PubMed ID: 33829783
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
6. MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Kalev P; Hyer ML; Gross S; Konteatis Z; Chen CC; Fletcher M; Lein M; Aguado-Fraile E; Frank V; Barnett A; Mandley E; Goldford J; Chen Y; Sellers K; Hayes S; Lizotte K; Quang P; Tuncay Y; Clasquin M; Peters R; Weier J; Simone E; Murtie J; Liu W; Nagaraja R; Dang L; Sui Z; Biller SA; Travins J; Marks KM; Marjon K
Cancer Cell; 2021 Feb; 39(2):209-224.e11. PubMed ID: 33450196
[TBL] [Abstract][Full Text] [Related]
7. mTORC1-independent translation control in mammalian cells by methionine adenosyltransferase 2A and S-adenosylmethionine.
Alam M; Shima H; Matsuo Y; Long NC; Matsumoto M; Ishii Y; Sato N; Sugiyama T; Nobuta R; Hashimoto S; Liu L; Kaneko MK; Kato Y; Inada T; Igarashi K
J Biol Chem; 2022 Jul; 298(7):102084. PubMed ID: 35636512
[TBL] [Abstract][Full Text] [Related]
8. Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
Li M; Konteatis Z; Nagaraja N; Chen Y; Zhou S; Ma G; Gross S; Marjon K; Hyer ML; Mandley E; Lein M; Padyana AK; Jin L; Tong S; Peters R; Murtie J; Travins J; Medeiros M; Liu P; Frank V; Judd ET; Biller SA; Marks KM; Sui Z; Reznik SK
J Med Chem; 2022 Mar; 65(6):4600-4615. PubMed ID: 35293760
[TBL] [Abstract][Full Text] [Related]
9. S-adenosylmethionine biosynthesis is a targetable metabolic vulnerability of cancer stem cells.
Strekalova E; Malin D; Weisenhorn EMM; Russell JD; Hoelper D; Jain A; Coon JJ; Lewis PW; Cryns VL
Breast Cancer Res Treat; 2019 May; 175(1):39-50. PubMed ID: 30712196
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic safety assessment via multi-omic characterisation of systemic pathway perturbations following in vivo MAT2A inhibition.
Fogal V; Michopoulos F; Jarnuczak AF; Hamza GM; Harlfinger S; Davey P; Hulme H; Atkinson SJ; Gabrowski P; Cheung T; Grondine M; Hoover C; Rose J; Bray C; Foster AJ; Askin S; Majumder MM; Fitzpatrick P; Miele E; Macdonald R; Keun HC; Coen M
Arch Toxicol; 2024 May; ():. PubMed ID: 38755480
[TBL] [Abstract][Full Text] [Related]
11. A patent review of MAT2a inhibitors (2018-2021).
Atkinson SJ; Evans L; Scott JS
Expert Opin Ther Pat; 2022 Oct; 32(10):1043-1053. PubMed ID: 36043503
[TBL] [Abstract][Full Text] [Related]
12. The combination of methionine adenosyltransferase 2A inhibitor and methyltransferase like 3 inhibitor promotes apoptosis of non-small cell lung cancer cells and produces synergistic anti-tumor activity.
Xuan YF; Lu S; Ou YJ; Bao XB; Huan XJ; Song SS; Miao ZH; Wang YQ
Biochem Biophys Res Commun; 2024 Jul; 716():150011. PubMed ID: 38704890
[TBL] [Abstract][Full Text] [Related]
13. Combined inhibition of MTAP and MAT2a mimics synthetic lethality in tumor models via PRMT5 inhibition.
Bedard GT; Gilaj N; Peregrina K; Brew I; Tosti E; Shaffer K; Tyler PC; Edelmann W; Augenlicht LH; Schramm VL
J Biol Chem; 2024 Jan; 300(1):105492. PubMed ID: 38000655
[TBL] [Abstract][Full Text] [Related]
14. S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells.
Lozano-Sepulveda SA; Bautista-Osorio E; Merino-Mascorro JA; Varela-Rey M; Muñoz-Espinosa LE; Cordero-Perez P; Martinez-Chantar ML; Rivas-Estilla AM
World J Gastroenterol; 2016 Apr; 22(14):3746-57. PubMed ID: 27076759
[TBL] [Abstract][Full Text] [Related]
15. The potential and challenges of targeting
Bray C; Balcells C; McNeish IA; Keun HC
Front Oncol; 2023; 13():1264785. PubMed ID: 37795443
[TBL] [Abstract][Full Text] [Related]
16. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Marjon K; Cameron MJ; Quang P; Clasquin MF; Mandley E; Kunii K; McVay M; Choe S; Kernytsky A; Gross S; Konteatis Z; Murtie J; Blake ML; Travins J; Dorsch M; Biller SA; Marks KM
Cell Rep; 2016 Apr; 15(3):574-587. PubMed ID: 27068473
[TBL] [Abstract][Full Text] [Related]
17. Expression of methionine adenosyltransferase 2A in renal cell carcinomas and potential mechanism for kidney carcinogenesis.
Wang X; Guo X; Yu W; Li C; Gui Y; Cai Z
BMC Cancer; 2014 Mar; 14():196. PubMed ID: 24636201
[TBL] [Abstract][Full Text] [Related]
18. Fragment-Based Design of a Potent MAT2a Inhibitor and
De Fusco C; Schimpl M; Börjesson U; Cheung T; Collie I; Evans L; Narasimhan P; Stubbs C; Vazquez-Chantada M; Wagner DJ; Grondine M; Sanders MG; Tentarelli S; Underwood E; Argyrou A; Smith JM; Lynch JT; Chiarparin E; Robb G; Bagal SK; Scott JS
J Med Chem; 2021 May; 64(10):6814-6826. PubMed ID: 33900758
[TBL] [Abstract][Full Text] [Related]
19. L-methionine availability regulates expression of the methionine adenosyltransferase 2A gene in human hepatocarcinoma cells: role of S-adenosylmethionine.
Martínez-Chantar ML; Latasa MU; Varela-Rey M; Lu SC; García-Trevijano ER; Mato JM; Avila MA
J Biol Chem; 2003 May; 278(22):19885-90. PubMed ID: 12660248
[TBL] [Abstract][Full Text] [Related]
20. Methionine adenosyltransferases in cancers: Mechanisms of dysregulation and implications for therapy.
Maldonado LY; Arsene D; Mato JM; Lu SC
Exp Biol Med (Maywood); 2018 Jan; 243(2):107-117. PubMed ID: 29141455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
